Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2018. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions were executed on October 12, 2018, following the dividend payment date of October 11, 2018.
Key Financial Metrics
The filing does not contain company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction data:
- Instrument Types: Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Price (Ordinary Shares): GBP 14.5879 per share.
- Transaction Price (ADSs): USD 38.2449 per ADS.
- Transaction Volume: Varied by individual executive, ranging from 0.013 shares to 2,012.555 shares for Ordinary Shares, and 19.611 to 470.948 for ADSs.
- Transaction Venues: London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. The only changes reported are the incremental increases in shareholdings for the listed executives resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of the transactions is strictly mechanical, described as "Acquisition of Ordinary Shares/ADSs following the re-investment of dividends paid to shareholders."
Investor Verification Checklist
- Verify the dividend reinvestment plan (DRIP) terms applicable to the October 11, 2018 dividend payment.
- Confirm the market price of GSK Ordinary Shares and ADSs on October 12, 2018, to validate the transaction prices of GBP 14.5879 and USD 38.2449.
- Review the total shareholding positions of the listed PDMRs (including CEO Emma Walmsley and CFO Simon Dingemans) post-transaction to assess concentration of ownership.
- Ensure compliance with insider trading regulations regarding the timing of these reinvestment transactions relative to material non-public information.